Sebastijan Hobor
Overview
Explore the profile of Sebastijan Hobor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
3488
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hobor S, Al Bakir M, Hiley C, Skrzypski M, Frankell A, Bakker B, et al.
Nat Commun
. 2024 Jun;
15(1):4871.
PMID: 38871738
The phenomenon of mixed/heterogenous treatment responses to cancer therapies within an individual patient presents a challenging clinical scenario. Furthermore, the molecular basis of mixed intra-patient tumor responses remains unclear. Here,...
2.
Venkatesan S, Angelova M, Puttick C, Zhai H, Caswell D, Lu W, et al.
Cancer Discov
. 2021 May;
11(10):2456-2473.
PMID: 33947663
APOBEC3 enzymes are cytosine deaminases implicated in cancer. Precisely when expression is induced during cancer development remains to be defined. Here we show that specific genes are upregulated in breast...
3.
Torres C, Wu M, Hobor S, Wainwright E, Martin M, Patel H, et al.
Nat Commun
. 2020 Apr;
11(1):1792.
PMID: 32286289
Continuous cancer growth is driven by subsets of self-renewing malignant cells. Targeting of uncontrolled self-renewal through inhibition of stem cell-related signaling pathways has proven challenging. Here, we show that cancer...
4.
Blagih J, Zani F, Chakravarty P, Hennequart M, Pilley S, Hobor S, et al.
Cell Rep
. 2020 Jan;
30(2):481-496.e6.
PMID: 31940491
Loss of p53 function contributes to the development of many cancers. While cell-autonomous consequences of p53 mutation have been studied extensively, the role of p53 in regulating the anti-tumor immune...
5.
Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, et al.
Cell
. 2018 Apr;
173(3):595-610.e11.
PMID: 29656894
The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients recruited into the multi-center prospective...
6.
Lopez-Garcia C, Sansregret L, Domingo E, McGranahan N, Hobor S, Birkbak N, et al.
Cancer Cell
. 2017 Jan;
31(1):79-93.
PMID: 28073006
Chromosomal instability (CIN) contributes to cancer evolution, intratumor heterogeneity, and drug resistance. CIN is driven by chromosome segregation errors and a tolerance phenotype that permits the propagation of aneuploid genomes....
7.
Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al.
Nat Med
. 2015 Jul;
21(7):827.
PMID: 26151329
No abstract available.
8.
Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al.
Nat Med
. 2015 Jun;
21(7):795-801.
PMID: 26030179
Colorectal cancers (CRCs) evolve by a reiterative process of genetic diversification and clonal evolution. The molecular profile of CRC is routinely assessed in surgical or bioptic samples. Genotyping of CRC...
9.
Arena S, Bellosillo B, Siravegna G, Martinez A, Canadas I, Lazzari L, et al.
Clin Cancer Res
. 2015 Jan;
21(9):2157-66.
PMID: 25623215
Purpose: Patients with colorectal cancer who respond to the anti-EGFR antibody cetuximab often develop resistance within several months of initiating therapy. To design new lines of treatment, the molecular landscape...
10.
Hobor S, Van Emburgh B, Crowley E, Misale S, Di Nicolantonio F, Bardelli A
Clin Cancer Res
. 2014 Jun;
20(24):6429-38.
PMID: 24916700
Purpose: Targeted inhibition of EGFR with the mAbs cetuximab or panitumumab is a valuable treatment for RAS wild-type colorectal cancers. The efficacy of EGFR blockade is limited by the emergence...